​​​​​​​CANVAS 1 and 2 trials: Two Phase III, randomised, double-blind, international, multicentre, comparative efficacy and safety trials comparing Zinforo (600 mg IV q12h ± placebo q12h, adjusted for moderate renal impairment) vs vancomycin + aztreonam (1 g IV q12h)²

Response rate at Day 3​​​​​​​

Clinical response rates at Day 3 (CANVAS 1 and 2 trials)^†3

Zinforo was well tolerated with a safety profile consistent with the cephalosporin class.²

*The lower limit of the 95% CI was above -10%, which met the predefined criteria for non-inferiority.^2
 ‡There is no experience with Zinforo in the treatment of cSSTI in the following patient groups: The immunocompromised; patients with severe sepsis/septic shock; necrotising fasciitis; perirectal abscess; and patients with third-degree and extensive burns. There is limited experience in treating patients with diabetic foot infections. Caution is advised when treating such patients.^1
†Zinforo was associated with a non-statistical significant early clinical response defined by cessation of lesion spread and absence of fever.³
**Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.¹